Penserra Capital Management LLC Makes New Investment in Medpace Holdings, Inc. $MEDP

Penserra Capital Management LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 988 shares of the company’s stock, valued at approximately $507,000.

Other large investors have also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC lifted its position in shares of Medpace by 2.6% during the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after purchasing an additional 19 shares in the last quarter. Portside Wealth Group LLC increased its stake in Medpace by 2.5% during the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after buying an additional 27 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in Medpace by 35.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after buying an additional 27 shares in the last quarter. M&T Bank Corp boosted its position in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Finally, Independent Advisor Alliance boosted its position in Medpace by 3.4% in the 3rd quarter. Independent Advisor Alliance now owns 1,044 shares of the company’s stock valued at $537,000 after buying an additional 34 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at $3,542,100. This represents a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 320,192 shares of company stock worth $192,909,762 over the last 90 days. 20.30% of the stock is owned by insiders.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $542.04 on Monday. The business has a 50-day moving average of $579.45 and a two-hundred day moving average of $539.04. The company has a market capitalization of $15.27 billion, a price-to-earnings ratio of 37.90, a price-to-earnings-growth ratio of 1.82 and a beta of 1.42. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92.

Analyst Ratings Changes

MEDP has been the topic of a number of recent research reports. Robert W. Baird set a $613.00 price objective on Medpace in a research report on Friday, October 24th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Truist Financial set a $555.00 price target on Medpace in a research report on Monday, October 27th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Finally, TD Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $491.27.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.